Skip to main content

Canopy Growth’s stock falls back from recent gains as cannabis stocks cool off

The optimism around a potential rescheduling of cannabis fades as 14 Republican members of Congress say pot should remain a Schedule I drug under federal law.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.